Physician profile
Hina Khan
NPI 1356662803
$33,545.68
in general payments reported to CMS, 2019-2025
17 companies · $14K in 2025
The $14K reported for 2025 was more than what 91% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,917 · 2021: $2,268 · 2022: $26.77 · 2023: $6,395 · 2024: $2,618 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $16K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,480 · Food and Beverage: $1,465 · Education: $45.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $16,344.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,480.00 |
| Food and Beverage | $1,464.72 |
| Education | $45.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $13,403.37 | 2019-2025 | |
| Eli Lilly and Company | $4,438.00 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $3,484.62 | 2019-2023 | |
| Daiichi Sankyo INC. | $2,820.00 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $2,306.50 | 2025 | Libtayo |
| Genzyme Corporation | $2,268.00 | 2021 | |
| Mirati Therapeutics, INC. | $2,187.50 | 2023 | Krazati |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,612.17 | 2025 | |
| Jazz Pharmaceuticals INC. | $250.76 | 2025 | |
| Janssen Biotech, INC. | $149.76 | 2023 | Rybrevant |
| Regeneron Pharmaceuticals, INC. | $147.83 | 2023 | Libtayo |
| Astrazeneca Uk Limited | $135.00 | 2024 | |
| Genentech USA, INC. | $114.49 | 2024-2025 | |
| Medtronic, INC. | $105.72 | 2025 | Signia |
| Agile Therapeutics, INC. | $64.90 | 2022-2024 | Twirla |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $45.12 | 2023 | |
| Integra Lifesciences Corporation | $11.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hina Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.